Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cullinan Therapeutics, Inc. (CGEM)

Cullinan Therapeutics reports interim velinotamig lupus data; 8 of 9 patients improved

Positive Impact 3 of 5 other

Cullinan Therapeutics furnished a press release and 8-K describing interim clinical data from a Phase 1b/2a trial of velinotamig in patients with refractory systemic lupus erythematosus. The trial is run by Genrix in China, and Cullinan holds the global (ex-Greater China) license, so the results bear on the company's lead clinical asset, though the data are early and based on a small number of patients.

Key points

  • As of the September 8, 2026 data cutoff, 12 patients had been treated across three multi-dose cohorts, with no dose-limiting toxicities and no ICANS reported
  • Cytokine release syndrome occurred in two patients, limited to Grade 1 or 2 events; no Grade 3 or higher CRS was observed
  • Eight of nine evaluable patients achieved a reduction of at least four points in SLEDAI-2K
  • Four of seven evaluable patients with proteinuria above 500 mg/24 hours at baseline achieved a complete renal response within 24 weeks

The filing

CompanyCullinan Therapeutics, Inc. (CGEM)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:20 AM ET
Accession number0001193125-26-452644

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:32 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.